Abbott Laboratories Company Insiders
ABT Stock | USD 118.95 0.99 0.84% |
Slightly above 67% of Abbott Laboratories' corporate insiders are selling. The analysis of insiders' sentiment of trading Abbott Laboratories stock suggests that many insiders are alarmed at this time. Abbott Laboratories employs about 114 K people. The company is managed by 49 executives with a total tenure of roughly 322 years, averaging almost 6.0 years of service per executive, having 2326.53 employees per reported executive.
Robert Ford CEO President, Chief Executive Officer, Chief Operating Officer, Director |
Miles White Chairman Chairman, CEO and Chairman of Executive Committee |
Abbott Laboratories' Insider Buying Vs Selling
33
Selling | Buying |
Latest Trades
2024-09-12 | Robert B Ford | Disposed 141679 @ 116.41 | View | ||
2024-09-04 | John James | Disposed @ 114.4 | |||
2024-08-19 | Josh Gottheimer | Acquired @ 111.91 | |||
2024-07-29 | Josh Gottheimer | Acquired @ 104.78 | |||
2024-07-23 | Thomas H. Kean, Jr. | Acquired @ 103.92 | |||
2024-07-05 | Jared Moskowitz | Acquired @ 104.02 | |||
2024-07-02 | Kathy E. Manning | Acquired @ 103.2 | |||
2024-05-10 | Jr. Robert E Funck | Disposed 10097 @ 104.57 | View | ||
2024-05-07 | Lisa D Earnhardt | Disposed 22852 @ 106.25 | View | ||
2024-03-01 | Daniel Gesua Sive Salvadori | Disposed 963 @ 118.5 | View | ||
2024-02-23 | Andrea F Wainer | Disposed 12500 @ 120 | View | ||
2024-01-29 | Andrea F Wainer | Disposed 42500 @ 112.5 | View | ||
2024-01-23 | Kathy E. Manning | Disposed @ 114 | |||
2024-01-17 | Thomas R. Carper | Disposed @ 113.96 | |||
2023-12-14 | Andrea F Wainer | Disposed 15000 @ 108 | View |
Monitoring Abbott Laboratories' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Abbott Laboratories' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Abbott Laboratories. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Abbott Laboratories' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Abbott |
Abbott Laboratories' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Abbott Laboratories' future performance. Based on our forecasts, it is anticipated that Abbott will maintain a workforce of slightly above 114000 employees by December 2024.Abbott Laboratories' latest congressional trading
Congressional trading in companies like Abbott Laboratories, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Abbott Laboratories by those in governmental positions are based on the same information available to the general public.
2024-09-18 | Representative Michael McCaul | Acquired $50K to $100K | Verify | ||
2024-09-11 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
2024-09-06 | Representative John James | Acquired Under $15K | Verify | ||
2024-09-02 | Representative John James | Acquired Under $15K | Verify | ||
2024-08-21 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
2024-08-19 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
2024-08-16 | Representative Kathy Manning | Acquired Under $15K | Verify | ||
2024-08-15 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
2024-02-02 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
2024-02-01 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
2023-11-01 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
2023-10-31 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
2023-10-20 | Senator Pete Ricketts | Acquired $100K to $250K | Verify | ||
2023-10-12 | Senator Markwayne Mullin | Acquired $15K to $50K | Verify | ||
2022-08-13 | Representative Dean Phillips | Acquired Under $15K | Verify | ||
2022-01-27 | Representative Michael C Burgess | Acquired Under $15K | Verify | ||
2019-04-24 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
2019-04-23 | Senator Tina Smith | Acquired $250K to $500K | Verify | ||
2018-05-05 | Representative Pete Sessions | Acquired Under $15K | Verify | ||
2015-08-03 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2015-08-02 | Senator Shelley Moore Capito | Acquired Under $15K | Verify |
Abbott Laboratories Management Team Effectiveness
The company has Return on Asset of 0.0649 % which means that on every $100 spent on assets, it made $0.0649 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1484 %, implying that it generated $0.1484 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024.Net Income Applicable To Common Shares is likely to gain to about 8.4 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.3 B in 2024.
Abbott Laboratories Workforce Comparison
Abbott Laboratories is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 468,000. Abbott Laboratories totals roughly 114,000 in number of employees claiming about 24% of equities under Health Care industry.
Abbott Laboratories Profit Margins
The company has Net Profit Margin of 0.14 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.19 %, which entails that for every 100 dollars of revenue, it generated $0.19 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.62 | 0.5518 |
|
| |||||
Net Profit Margin | 0.15 | 0.1427 |
|
| |||||
Operating Profit Margin | 0.21 | 0.1615 |
|
| |||||
Pretax Profit Margin | 0.21 | 0.1661 |
|
| |||||
Return On Assets | 0.12 | 0.0782 |
|
| |||||
Return On Equity | 0.26 | 0.1483 |
|
|
Abbott Laboratories Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abbott Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abbott Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Abbott Laboratories insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.25 | 1 | 4 | 157,421 | 314,842 |
2024-09-01 | 0.75 | 6 | 8 | 142,668 | 284,380 |
2024-06-01 | 4.75 | 19 | 4 | 48,238 | 43,315 |
2024-03-01 | 1.2273 | 27 | 22 | 1,053,564 | 190,315 |
2023-12-01 | 1.25 | 5 | 4 | 16,023 | 80,000 |
2023-09-01 | 0.8333 | 10 | 12 | 31,608 | 85,956 |
2023-06-01 | 4.2 | 21 | 5 | 60,705 | 74,452 |
2023-03-01 | 1.122 | 46 | 41 | 1,621,195 | 165,915 |
2022-12-01 | 1.6 | 8 | 5 | 1,942 | 65,421 |
2022-09-01 | 0.6875 | 11 | 16 | 127,641 | 390,359 |
2022-06-01 | 2.0909 | 23 | 11 | 67,642 | 149,379 |
2022-03-01 | 1.2083 | 58 | 48 | 2,375,058 | 251,024 |
2021-12-01 | 0.48 | 24 | 50 | 440,718 | 1,105,201 |
2021-09-01 | 0.8077 | 21 | 26 | 305,674 | 579,836 |
2021-06-01 | 1.5714 | 22 | 14 | 168,725 | 244,712 |
2021-03-01 | 0.9375 | 60 | 64 | 2,895,472 | 986,184 |
2020-12-01 | 1.1818 | 13 | 11 | 171,076 | 286,933 |
2020-09-01 | 0.4583 | 11 | 24 | 225,482 | 461,654 |
2020-06-01 | 1.1429 | 32 | 28 | 442,677 | 675,358 |
2020-03-01 | 0.8507 | 57 | 67 | 3,877,676 | 1,676,057 |
2019-12-01 | 0.4444 | 4 | 9 | 16,959 | 58,383 |
2019-09-01 | 0.6 | 12 | 20 | 290,678 | 443,843 |
2019-06-01 | 1.3 | 52 | 40 | 1,874,831 | 2,900,820 |
2019-03-01 | 0.2027 | 59 | 291 | 4,353,816 | 2,899,476 |
2018-12-01 | 0.0676 | 5 | 74 | 391,185 | 797,682 |
2018-09-01 | 0.0984 | 12 | 122 | 335,500 | 745,101 |
2018-06-01 | 1.2778 | 23 | 18 | 139,547 | 57,471 |
2018-03-01 | 0.3958 | 114 | 288 | 5,292,299 | 1,761,436 |
2017-12-01 | 0.0843 | 15 | 178 | 738,591 | 1,578,706 |
2017-09-01 | 0.6 | 27 | 45 | 1,085,721 | 1,240,503 |
2017-06-01 | 0.9333 | 28 | 30 | 482,483 | 426,674 |
2017-03-01 | 0.8214 | 69 | 84 | 6,435,881 | 1,264,072 |
2016-12-01 | 33.0 | 165 | 5 | 432,527 | 48,864 |
2016-09-01 | 6.7619 | 142 | 21 | 1,451,358 | 928,993 |
2016-06-01 | 1.5 | 21 | 14 | 67,678 | 62,773 |
2016-03-01 | 0.6849 | 50 | 73 | 7,484,727 | 544,250 |
2015-12-01 | 0.5625 | 9 | 16 | 441,362 | 952,910 |
2015-09-01 | 0.5385 | 7 | 13 | 76,866 | 132,908 |
2015-06-01 | 1.0 | 24 | 24 | 480,134 | 138,279 |
2015-03-01 | 0.3592 | 37 | 103 | 3,355,163 | 450,749 |
2014-12-01 | 1.3333 | 12 | 9 | 449,921 | 889,528 |
2014-09-01 | 1.625 | 13 | 8 | 221,346 | 197,061 |
2014-06-01 | 1.8571 | 13 | 7 | 59,246 | 57,559 |
2014-03-01 | 0.6923 | 36 | 52 | 2,576,964 | 356,144 |
2013-12-01 | 0.2903 | 18 | 62 | 366,337 | 727,860 |
2013-09-01 | 1.2 | 6 | 5 | 264,503 | 17,993 |
2013-06-01 | 1.1667 | 14 | 12 | 190,587 | 131,836 |
2013-03-01 | 0.7755 | 38 | 49 | 3,820,644 | 1,116,549 |
2012-12-01 | 0.3226 | 30 | 93 | 905,506 | 1,573,525 |
2012-09-01 | 0.3333 | 31 | 93 | 449,538 | 716,621 |
2012-06-01 | 0.2727 | 21 | 77 | 168,058 | 295,464 |
2012-03-01 | 0.3035 | 61 | 201 | 2,294,158 | 1,784,012 |
2011-12-01 | 0.0754 | 23 | 305 | 1,277,617 | 2,491,533 |
2011-09-01 | 0.3333 | 6 | 18 | 4,371 | 27,954 |
2011-06-01 | 0.1203 | 16 | 133 | 51,537 | 293,863 |
2011-03-01 | 0.2927 | 36 | 123 | 1,599,018 | 507,838 |
2010-12-01 | 0.44 | 11 | 25 | 36,377 | 112,222 |
2010-09-01 | 0.3235 | 11 | 34 | 119,723 | 81,620 |
2010-06-01 | 0.4118 | 14 | 34 | 44,997 | 125,590 |
2010-03-01 | 0.3443 | 63 | 183 | 1,898,904 | 837,459 |
2009-12-01 | 0.337 | 31 | 92 | 410,131 | 821,439 |
2009-09-01 | 1.6667 | 5 | 3 | 16,432 | 36,086 |
2009-06-01 | 1.0833 | 13 | 12 | 25,848 | 77,067 |
2009-03-01 | 0.343 | 83 | 242 | 2,773,753 | 1,725,305 |
2008-12-01 | 1.3846 | 18 | 13 | 15,690 | 31,855 |
2008-09-01 | 0.6989 | 65 | 93 | 2,356,069 | 2,567,373 |
2008-06-01 | 0.8039 | 41 | 51 | 247,756 | 228,464 |
2008-03-01 | 0.4029 | 83 | 206 | 2,857,891 | 1,505,093 |
2007-12-01 | 0.973 | 36 | 37 | 426,835 | 515,440 |
2007-09-01 | 0.4976 | 102 | 205 | 3,706,478 | 4,578,169 |
2007-06-01 | 1.2143 | 17 | 14 | 51,854 | 92,713 |
2007-03-01 | 0.8068 | 142 | 176 | 4,811,581 | 2,820,938 |
2006-12-01 | 0.4211 | 8 | 19 | 37,604 | 44,993 |
2006-09-01 | 0.9231 | 36 | 39 | 845,791 | 906,297 |
2006-06-01 | 0.6774 | 21 | 31 | 175,617 | 162,010 |
2006-03-01 | 0.8169 | 58 | 71 | 2,606,390 | 743,051 |
2005-12-01 | 0.4444 | 4 | 9 | 1,711 | 29,564 |
2005-09-01 | 1.3333 | 4 | 3 | 1,590 | 38,121 |
2005-06-01 | 1.7692 | 23 | 13 | 162,714 | 93,191 |
2005-03-01 | 1.1053 | 42 | 38 | 2,266,181 | 1,292,492 |
2004-12-01 | 0.8125 | 26 | 32 | 162,717 | 218,438 |
2004-09-01 | 0.7 | 7 | 10 | 87,786 | 109,476 |
2004-06-01 | 1.5 | 18 | 12 | 81,865 | 63,792 |
2004-03-01 | 1.1111 | 30 | 27 | 1,355,904 | 561,185 |
2003-12-01 | 0.5263 | 10 | 19 | 196,053 | 117,752 |
2003-09-01 | 0.7778 | 7 | 9 | 133,025 | 141,205 |
2003-06-01 | 0.6667 | 2 | 3 | 12,367 | 36,651 |
2003-03-01 | 0.0909 | 1 | 11 | 15,266 | 180,783 |
Abbott Laboratories Notable Stakeholders
An Abbott Laboratories stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Abbott Laboratories often face trade-offs trying to please all of them. Abbott Laboratories' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Abbott Laboratories' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert Ford | President, Chief Executive Officer, Chief Operating Officer, Director | Profile | |
Miles White | Chairman, CEO and Chairman of Executive Committee | Profile | |
Roger Bird | Senior Vice President - U.S. Nutrition | Profile | |
Hubert Allen | Executive Vice President, General Counsel, Secretary | Profile | |
Jared Watkin | Senior Vice President - Diabetes Care | Profile | |
Jaime Contreras | Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | Profile | |
Andrew Lane | Senior Vice President - Established Pharmaceuticals, Emerging Markets | Profile | |
John Capek | Executive Vice President - Ventures | Profile | |
Joseph Manning | Senior Vice President - Abbott Nutrition International | Profile | |
Robert Funck | Chief Financial Officer, Executive Vice President - Finance | Profile | |
Daniel Salvadori | Senior Vice President - Established Pharmaceuticals, Latin America. | Profile | |
Samuel Scott | Independent Director | Profile | |
Phebe Novakovic | Independent Director | Profile | |
Roxanne Austin | Independent Director | Profile | |
Sally Blount | Independent Director | Profile | |
Daniel Starks | Independent Director | Profile | |
Robert Alpern | Independent Director | Profile | |
Glenn Tilton | Independent Director | Profile | |
Darren McDew | Independent Director | Profile | |
Patricia Gonzalez | Independent Director | Profile | |
Nancy McKinstry | Independent Director | Profile | |
Michelle Kumbier | Independent Director | Profile | |
Edward Liddy | Independent Director | Profile | |
John Stratton | Independent Director | Profile | |
William Osborn | Lead Independent Director | Profile | |
Hubert JD | General VP | Profile | |
Erica Battaglia | VP Officer | Profile | |
Christopher Scoggins | Senior Vice President - Rapid Diagnostics | Profile | |
Michael Dale | Senior Vice President - Structural Heart | Profile | |
Sammy Karam | Senior Vice President - Established Pharmaceuticals, Emerging Markets | Profile | |
Michael Pederson | Senior Vice President - Electrophysiology and Heart Failure | Profile | |
Lisa Earnhardt | Executive Vice President - Medical Devices | Profile | |
Alejandro Wellisch | Senior Vice President - Established Pharmaceuticals, Latin America | Profile | |
Christopher Calamari | Senior Vice President - U.S. Nutrition | Profile | |
Charles Brynelsen | Senior Vice President - Abbott Vascular | Profile | |
Gregory Ahlberg | Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | Profile | |
Philip Boudreau | Vice President - Finance, Controller | Profile | |
John Ginascol | Executive Vice President - Core Diagnostics | Profile | |
Michael Roman | Independent Director | Profile | |
Mary Moreland | Executive Vice President of Human Resources | Profile | |
Sabina Ewing | Senior Officer | Profile | |
Randel Woodgrift | Senior Vice President - CRM | Profile | |
Elaine Leavenworth | VP Officer | Profile | |
Michael Comilla | Vice Relations | Profile | |
Scott Leinenweber | Acquisitions Licensing | Profile | |
James Young | VP Officer | Profile | |
Louis Morrone | Senior Vice President - Rapid Diagnostics | Profile | |
Andrea Wainer | Executive Vice President - Rapid and Molecular Diagnostics | Profile | |
Melissa Brotz | Vice Marketing | Profile |
About Abbott Laboratories Management Performance
The success or failure of an entity such as Abbott Laboratories often depends on how effective the management is. Abbott Laboratories management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Abbott management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Abbott management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.14 | 0.17 | |
Return On Capital Employed | 0.11 | 0.10 | |
Return On Assets | 0.08 | 0.12 | |
Return On Equity | 0.15 | 0.26 |
Please note, the imprecision that can be found in Abbott Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Abbott Laboratories. Check Abbott Laboratories' Beneish M Score to see the likelihood of Abbott Laboratories' management manipulating its earnings.
Abbott Laboratories Workforce Analysis
Traditionally, organizations such as Abbott Laboratories use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Abbott Laboratories within its industry.Abbott Laboratories Manpower Efficiency
Return on Abbott Laboratories Manpower
Revenue Per Employee | 351.8K | |
Revenue Per Executive | 818.6M | |
Net Income Per Employee | 50.2K | |
Net Income Per Executive | 116.8M | |
Working Capital Per Employee | 77.4K | |
Working Capital Per Executive | 180.2M |
Additional Tools for Abbott Stock Analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.